$XTALPI(02228.HK), Jingtai Technology (2228.HK) incubated company ReviR Xili Technology (hereinafter referred to as "ReviR") has obtained the "Drug Clinical Trial Approval Notice" for the small molecule pipeline RTX-117 for the treatment of Charcot-Marie-Tooth disease (CMT) issued by the National Medical Products Administration (NMPA). The Phase I clinical trial is scheduled to commence in the first quarter of 2026. RTX-117 is the first Class 1 innovative drug pipeline targeting CMT in China, and it is also the first project in a series of rare disease drug pipelines developed by ReviR in collaboration with Jingtai Technology using AI+robot-assisted R&D to enter clinical trials. Jingtai Technology will receive corresponding milestone payments and has the right to participate in the sales sharing and subsequent licensing revenue sharing of this pipeline. Previously, this pipeline has obtained the IND approval and Orphan Drug Designation (ODD) from the U.S. FDA, qualifying for FDA priority review and longer overseas market exclusivity.